This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in
participants aged 6 months to <6 years, when administered as a primary series in SARS-CoV-2
vaccine-naïve participants (Part 1) and a single booster dose given to participants who
previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2).
Part 1 will enroll participants aged 6 months to <6 years who have not been previously
vaccinated against SARS-CoV-2. Participants will receive 2 doses of the mRNA-1273.214 vaccine
and will be followed for approximately 12 months after the second dose for safety and
additional immunogenicity follow-up.
Part 2 will enroll participants aged 6 months to <6 years who have previously been vaccinated
with a mRNA-1273 primary series in Study mRNA-1273-P204. Participants will receive a single
booster dose of the mRNA-1273.214 vaccine, at least 4 months after completion of the
mRNA-1273 primary series and will be followed for approximately 6 months after the booster
dose for safety and immunogenicity.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.